1-8 of 8
Robert Irons
Close
Sort by
Journal Articles

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways

Jessica L. Allen, Matthew S. Fore, Jenna Wooten, Philip A. Roehrs, Nazmim S. Bhuiya, Todd Hoffert, Andrew Sharf, Allison M. Deal, Paul Armistead, James Coghill, Don A. Gabriel, Robert Irons, Amber Essenmacher, Thomas C. Shea, Kristy Richards, Corey Cutler, Jerome Ritz, Jonathan Serody, Albert S. Baldwin, Stefanie Sarantopoulos
Journal: Blood
Blood (2012) 120 (12): 2529–2536.
https://doi.org/10.1182/blood-2012-06-438911
Published: 2012
Journal Articles

The Efficacy and Safety of VP-16 and G-CSF as a Mobilization Regimen Prior to Autologous Stem Cell Transplantation (ASCT) for Patients (Pts) with Multiple Myeloma (MM) and Lymphoma.

William A. Wood, MD, MPH, Julia Whitley, Dominic T Moore, PhD, Jonathan S Serody, MD, Don A. Gabriel, MD, PhD, James M. Coghill, MD, Robert Irons, PA-C, Thomas C. Shea, MD
Journal: Blood
Blood (2009) 114 (22): 4225.
https://doi.org/10.1182/blood.V114.22.4225.4225
Published: 2009
Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD
Journal: Blood
Blood (2007) 110 (11): 4940.
https://doi.org/10.1182/blood.V110.11.4940.4940
Published: 2007
Journal Articles

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Larry W. Buie, PharmD, Kamakshi V. Rao, PharmD, Stacy Epstein, PharmD, Thomas C. Shea, MD, Terrence Comeau, MD, Don A. Gabriel, MD PhD, Robert Irons, PA, Barbara Eron, RN, Jonathan Serody, MD PhD
Journal: Blood
Blood (2007) 110 (11): 3007.
https://doi.org/10.1182/blood.V110.11.3007.3007
Published: 2007
Journal Articles

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Anne W. Beaven, MD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Dominic T. Moore, MS, MPH, Li Lin, MS, Andrew Sharf, RN, Carol Krasnov, Mark E. Brecher, MD, Jonathan Serody, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 5385.
https://doi.org/10.1182/blood.V106.11.5385.5385
Published: 2005
Journal Articles

Clinical and Pharmacokinetic Results of a Four-Day Continuous Infusion of Full-Dose Busulfan in Patients (pts) Undergoing Matched Related (MRD) or Unrelated (MUD) Stem Cell Transplant (SCT).

Thomas C. Shea, MD, Christine Walko, PharmD, Don Gabriel, MD, PhD, Jon Serody, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Andrew Gilman, MD, Carol Krasnov, Andrew Sharf, RN, Celeste Lindley, PharmD
Journal: Blood
Blood (2005) 106 (11): 1752.
https://doi.org/10.1182/blood.V106.11.1752.1752
Published: 2005
Journal Articles

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

Don A. Gabriel, MD, PhD, James Coghill, MD, Thomas C. Shea, MD, Terrance Comeau, MD, Robert Irons, P-AC, Carol Krasnov
Journal: Blood
Blood (2004) 104 (11): 5120.
https://doi.org/10.1182/blood.V104.11.5120.5120
Published: 2004
Journal Articles

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Thomas C. Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Donald Harvey, PharmD, Robert Irons, PA, David Morris, MD, Andrew Sharf, RN, Carol Krasnov, Cherie Dunphy, MD, Nicholas Banderenko, MD, Mark Brecher, MD
Journal: Blood
Blood (2004) 104 (11): 1826.
https://doi.org/10.1182/blood.V104.11.1826.1826
Published: 2004